4/A//SEC Filing
Giffin Brett A. 4/A
Accession 0000950170-23-066386
CIK 0001492674other
Filed
Nov 27, 7:00 PM ET
Accepted
Nov 28, 4:00 PM ET
Size
8.5 KB
Accession
0000950170-23-066386
Insider Transaction Report
Form 4/AAmended
Giffin Brett A.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-02-20$0.65/sh−537$349→ 3,049 total - Exercise/Conversion
Restricted Stock Units
2023-02-20−1,333→ 2,667 total→ Common Stock (1,333 underlying) - Exercise/Conversion
Common Stock
2023-02-20+1,333→ 3,586 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The original Form 4 filed on March 9, 2023 is amended by this Form 4 amendment to correct the amount of securities beneficially owned following the reported transactions.
- [F3]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021.
- [F4]On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001892921
Filing Metadata
- Form type
- 4/A
- Filed
- Nov 27, 7:00 PM ET
- Accepted
- Nov 28, 4:00 PM ET
- Size
- 8.5 KB